TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31796939
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative gentamicin treatment).
Study: 31796953
Drug: High-fructose diet
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose diet (150 g daily) for 8 weeks
Study: 31797105
Drug: IgM-enriched immunoglobulins
Normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-enriched immunoglobulins (Pentaglobin) 250 mg/kg (5 mL/kg) per day for 72 hours
Study: 31798447
Drug: Ayahuasca (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (one dose)
Study: 31798754
Drug: Protein-enriched milk
Normalized name: milk protein concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-enriched milk (2 × 20 g protein/day)
Study: 31799207
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sorafenib and hepatic arterial infusion chemotherapy
Study: 31799498
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors (infliximab, etanercept, adalimumab, MTX)
Study: 31801624
Drug: Utomilumab 1.2-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utomilumab 1.2-5 mg/kg or 100 mg flat dose every 4 weeks plus mogamulizumab 1 mg/kg (weekly in Cycle 1 followed by biweekly in Cycles ≥2)
Study: 31801624
Drug: Utomilumab/mogamulizumab combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utomilumab/mogamulizumab combination
Study: 31801732
Drug: Tremelimumab monotherapy
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab monotherapy (750 mg via intravenous infusion every 4 weeks for seven cycles, then every 12 weeks for two additional cycles)
Study: 31804299
Drug: Higher Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher Sequential Organ Failure Assessment score
Study: 31804669
Drug: Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide single-tablet regimen
Study: 31806397
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum betaine <77.7 μmol/L
Study: 31806397
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum betaine ≥77.7 μmol/L
Study: 31806613
Drug: Metoprolol optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol optimal dosing pathway
Study: 31807036
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) treatment starting from the second trimester (24-27 weeks)
Study: 31807036
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) treatment starting from the third trimester (28-30 weeks)
Study: 31809725
Drug: Recombinant E1E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant E1E2 complex vaccine
Study: 31810978
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cholinesterase inhibitor and memantine
Study: 31813938
Drug: 6-mercaptopurine (6MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine (6MP) 55-75 mg/m
Study: 31814209
Drug: One-session virtual
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session virtual reality exposure treatment (VRET)
Study: 31814753
Drug: Oliceridine IV
Normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oliceridine IV (G-protein selective agonist at the µ-opioid receptor)
Study: 31817795
Drug: 4G8-SDIE (Fc-optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4G8-SDIE (Fc-optimized FLT3 antibody)
Study: 31817885
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of extracts of restharrow root, Java tea, and goldenrod herb (Aqualibra)
Study: 31819193
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro assays with metformin
Study: 31819674
Drug: Intravenous amisulpride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amisulpride, 10 mg dose
Study: 31820038
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity (Matsuda Insulin Sensitivity Index; IS)
Study: 31820038
Drug: Insulin production
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin production
Study: 31820038
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in glucose metabolism
Study: 31820199
Drug: Pemetrexed/Erlotinib (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed/Erlotinib (pemetrexed 500 mg/m2)
Study: 31820981
Drug: Covalent inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covalent inhibitor of KRAS (specific dosage and duration not mentioned)
Study: 31821172
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg d6-α-tocopherol
Study: 31821172
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg d6-α-tocopherol
Study: 31821456
Drug: Vedolizumab IV
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV 75 mg
Study: 31821456
Drug: Vedolizumab IV
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV 300 mg
Study: 31821530
Drug: High oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oral splint
Study: 31822542
Drug: Standardised diagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised diagnostic and treatment algorithm involving neurologists and cardiologists; transesophageal echocardiogram for patients depending on age strata; implantable cardiac monitor for all patients; PFO closure planned for patients <60 years with PFO and no AF evidence within 6 months after stroke.
Study: 31823806
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) 60 mg once per month for three consecutive months
Study: 31823832
Drug: Vorinostat, starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat, starting dose 180 mg/m², intra-patient dose escalation until maximum tolerated dose (MTD)
Study: 31824412
Drug: Intravenous Thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Thrombolysis
Study: 31826340
Drug: Asciminib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asciminib (10 to 200 mg, administered once or twice daily)
Study: 31827803
Drug: Antibiotics administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics administration
Study: 31827803
Drug: Adrenergic agent
Normalized name: ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic agent administration
Study: 31828307
Drug: Increased sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased sex chromosome dosage
Study: 31828337
Drug: Aztreonam/avibactam loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam/avibactam loading dose of 500/137 mg (30 min infusion), followed by maintenance doses of 1500/410 mg (3 h infusions) q6h (Cohort 1)
Study: 31828337
Drug: Aztreonam/avibactam loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam/avibactam loading dose of 500/167 mg (30 min infusion), followed by maintenance doses of 1500/500 mg (3 h infusions) q6h (Cohorts 2+3)
Study: 31828337
Drug: IV metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV metronidazole 500 mg q8h (all patients)
Study: 31828337
Drug: Aztreonam/avibactam treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam/avibactam treatment
Study: 31829203
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) at a starting dose of 50 Gy in 5 fractions every other day (biologically effective dose: 100 Gy)
Study: 31831072
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model for daily evolution of disease severity
Study: 31832624
Drug: Immunoadsorption (IA)
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoadsorption (IA) - 2.0-fold individual total plasma volume on day 1, 2.5-fold on days 2-5, 5 treatments over 5 consecutive days.
Study: 31832624
Drug: Plasma Exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Exchange (PE) - 2 liters of plasma removed each day, substituted by 5% human albumin solution, 5 treatments over 5 consecutive days.
Study: 31833010
Drug: V-Go insulin
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: V-Go insulin delivery device
Study: 31835236
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (G) 1000 mg/m² combined with Pazopanib (P) for a median of 3.8 months
Study: 31835495
Drug: BAY 1125976
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1125976 (allosteric AKT inhibitor)
Study: 31836928
Drug: Ceftazidime-avibactam (2000/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime-avibactam (2000/500 mg by 2-h intravenous infusion every 8 h, adjusted for renal function)
Study: 31836927
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg twice-daily oral administration of cimetidine
Study: 31836927
Drug: lucerastat administered
Normalized name: Lucerastat
DrugBank: Lucerastat (DB14872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lucerastat administered alone
Study: 31839594
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (< 10 ng/mL)
Study: 31839594
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D low level (10-29.9 ng/mL)
Study: 31839594
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D normal level (≥ 30 ng/mL)
Study: 31839959
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) measured in plasma after a three-day oral gluten challenge.
Study: 31839959
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of tetramer-binding, CD4 + effector memory T cells (tetramer + β7 + T cells) after a three-day oral gluten challenge.
Study: 31839997
Drug: Pandemic influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic influenza virus vaccine (AS03-adjuvanted)
Study: 31839997
Drug: Pandemic influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic influenza virus vaccine (A/H9N2)
Study: 31839997
Drug: Chimeric HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric HA stalk-based universal influenza virus vaccine
Study: 31843865
Drug: Oral meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral meloxicam (preclinical only)
Study: 31844684
Drug: Weight reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight reduction followed by IVF treatment
Study: 31844684
Drug: IVF treatment-only
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatment-only
Study: 31845423
Drug: Higher L/A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher L/A ratios in children with overweight/obesity compared to normal weight children
Study: 31845423
Drug: Upper quartile
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper quartile L/A ratio in girls with overweight/obesity
Study: 31845423
Drug: Upper quartile
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper quartile L/A ratio in boys with overweight/obesity
Study: 31847861
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) treatment during adjuvant chemotherapy
Study: 31848762
Drug: Submerged two-stage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submerged two-stage implants
Study: 31848762
Drug: Nonsubmerged one-stage
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsubmerged one-stage implants
Study: 31848820
Drug: Preoperative high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative high protein β-hydroxy-β-methyl butyrate oral nutritional support (ONS)
Study: 31848820
Drug: Postoperative nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative nutritional support targeting at least 1 g/kg/day protein and 20 kcal/kg/day caloric intake
Study: 31849202
Drug: Ra-223 (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ra-223 (55 kBq/kg intravenously every 4 weeks) up to 6 cycles with endocrine therapy
Study: 31849542
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg/week plus MTX (ETN+MTX)
Study: 31850192
Drug: Nivolumab (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (exact dosage and duration not specified)
Study: 31850360
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g milk protein concentrate, 25 g maltodextrin, 7.75 g canola oil (treatment group)
Study: 31850853
Drug: Resident-run oral
Normalized name: Prevident Oral Paste Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resident-run oral health campaigns
Study: 31851518
Drug: DNA-PKcs inhibitors
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA-PKcs inhibitors with good PI3 kinase selectivity
Study: 31851762
Drug: Busulfan dosing
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan dosing based on fat free mass (FFM)
Study: 31851762
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing based on total body mass
Study: 31852810
Drug: TLC388 (Lipotecan)
Normalized name: Lipotecan
DrugBank: Lipotecan (DB17385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC388 (Lipotecan) Hydrochloride, 40 mg/m², administered for a median of 2 treatment cycles (range, 0-6)
Study: 31852847
Drug: Intermittent prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent prednisone administration
Study: 31852847
Drug: Chronic daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic daily steroid use
Study: 31853198
Drug: CC-115 10
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-115 10 mg BID
Study: 31853198
Drug: CC-115 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-115 (various doses 0.5-40 mg/day)
Study: 31853198
Drug: CC-115 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-115 (10 mg BID)
Study: 31853198
Drug: CC-115 (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-115 (in bioavailability substudy)
Study: 31853198
Drug: CC-115 (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-115 (in cohort expansion)
Study: 31853198
Drug: CC-115 (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-115 (in chronic lymphocytic leukemia/small lymphocytic lymphoma)
Study: 31853265
Drug: Capmatinib 300
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 300 mg BID
Study: 31857311
Drug: Antibiotic prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescription (yes/no)
Study: 31857311
Drug: Antibiotic requests
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic requests
Study: 31858327
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg every 12 hours for six doses in a 7-day lead-in cycle (cycle 0) followed by 60 mg every 12 hours for six doses in a 14-day cycle (cycle 1)
Study: 31859468
Drug: Polypodium leucotomos
Normalized name: Polypodium leucotomos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypodium leucotomos extract (PLE) 480 mg daily for 28 days
Study: 31860140
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) 1.8 mg/kg with MEC (mitoxantrone, etoposide, cytarabine)
Study: 31861009
Drug: Omadacycline (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omadacycline (oral form)
Study: 31863283
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg starting dose
Study: 31863283
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg starting dose in Del19-positive patients
Study: 31863283
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg starting dose in Asian patients
Study: 31863305
Drug: CYP2D6-specific drugs
Normalized name: PACIFIC OYSTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2D6-specific drugs
Study: 31865734
Drug: Hydrogen-oxygen therapy
Normalized name: carbon dioxide / helium / hydrogen / nitrogen / oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-oxygen therapy for 0.5, 1, and 2 months
Study: 31866281
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg orally twice per day in 28-day cycles until disease progression or unacceptable toxicity
Study: 31866516
Drug: Levonorgestrel 52-mg
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel 52-mg intrauterine system
Study: 31868997
Drug: Androgen-deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-deprivation therapy (32%)
Study: 31869400
Drug: Anthracycline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline treatment (86% epirubicin, 7% doxorubicin)
Study: 31869413
Drug: Allogeneic hematopoietic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with donor lymphocyte infusions (DLI) for mixed chimerism or residual or relapsed disease.
Study: 31869417
Drug: NK cells
Normalized name: NK Cells
DrugBank: Natural Killer Cell (DB15721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK cells expressing 3 inhibitory receptors (KIR2DL1/2DL3/3DL1)
Study: 31872928
Drug: Single-agent pazopanib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent pazopanib at a dose of 800 mg daily
Study: 31875196
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg/d for 14 weeks
Study: 31875931
Drug: Dotinurad 2
Normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Dotinurad 2 mg/day
Study: 31875931
Drug: Dotinurad 4
Normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Dotinurad 4 mg/day
Study: 31876107
Drug: Sirolimus combined
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus combined with oral metronomic therapy (twice daily celecoxib, alternating etoposide and cyclophosphamide every three weeks)
Study: 31876911
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg twice daily for a median of 41 months (range 0.2-58 months)
Study: 31876927
Drug: Coronary sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary sinus neuropeptide Y (CS NPY) levels ≥ 130 pg/mL
Study: 31879842
Drug: Lanreotide autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide autogel 120 mg/28 days
Study: 31881608
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression devices
Study: 31881853
Drug: Trametinib (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (daily oral at full dose for 18 cycles of 28 days)
Study: 31884564
Drug: Bimatoprost SR
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost SR 6 µg
Study: 31884564
Drug: Bimatoprost SR
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost SR 10 µg
Study: 31884564
Drug: Bimatoprost SR
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost SR 15 µg
Study: 31884564
Drug: Bimatoprost SR
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost SR 20 µg
Study: 31884564
Drug: Topical bimatoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bimatoprost 0.03% (Control)
Study: 31884564
Drug: Overall study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall study eyes (all doses combined)
Study: 31884676
Drug: GSK's IIV4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK's IIV4 (one dose)
Study: 31884676
Drug: GSK's IIV4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK's IIV4 (second dose)
Study: 31885349
Drug: Chemotherapy (N-chemo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (N-chemo group)
Study: 31885750
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mepolizumab (subcutaneous)
Study: 31887431
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg qd)